270 related articles for article (PubMed ID: 26842174)
21. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful?
Gunderson CC; Farrell R; Dinh BC; Thomas ED; Vesely SK; Lauer JK; Kao L; Chopra S; McMeekin DS; Moore KN
Gynecol Oncol; 2013 Sep; 130(3):411-5. PubMed ID: 23791827
[TBL] [Abstract][Full Text] [Related]
22. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
Weycker D; Barron R; Kartashov A; Legg J; Lyman GH
J Oncol Pharm Pract; 2014 Jun; 20(3):190-8. PubMed ID: 23824496
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of Serum Procalcitonin Levels in Patients With Febrile Neutropenia Presenting to the Emergency Department.
Yadav S; Mathew R; Sahu AK; Jamshed N; Mohindra R; Aggarwal P; Batra A; Halder D; Brunda RL
J Emerg Med; 2021 May; 60(5):641-647. PubMed ID: 33518374
[TBL] [Abstract][Full Text] [Related]
24. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.
de Souza Viana L; Serufo JC; da Costa Rocha MO; Costa RN; Duarte RC
Support Care Cancer; 2008 Jul; 16(7):841-6. PubMed ID: 17960431
[TBL] [Abstract][Full Text] [Related]
25. Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association.
Ba Y; Shi Y; Jiang W; Feng J; Cheng Y; Xiao L; Zhang Q; Qiu W; Xu B; Xu R; Shen B; Luo Z; Xie X; Chang J; Wang M; Li Y; Shuang Y; Niu Z; Liu B; Zhang J; Zhang L; Yao H; Xie C; Huang H; Liao W; Chen G; Zhang X; An H; Deng Y; Gong P; Xiong J; Yao Q; An X; Chen C; Shi Y; Wang J; Wang X; Wang Z; Xing P; Yang S; Zhou C
Cancer Biol Med; 2020 Nov; 17(4):896-909. PubMed ID: 33299642
[TBL] [Abstract][Full Text] [Related]
26. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
Cherif H; Johansson E; Björkholm M; Kalin M
Haematologica; 2006 Feb; 91(2):215-22. PubMed ID: 16461306
[TBL] [Abstract][Full Text] [Related]
27. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms.
Combariza JF; Lombana M; Pino LE; Arango M
Support Care Cancer; 2015 Apr; 23(4):1009-13. PubMed ID: 25270848
[TBL] [Abstract][Full Text] [Related]
28. Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score as a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors.
Bitar RA
Perm J; 2015; 19(3):37-47. PubMed ID: 26176568
[TBL] [Abstract][Full Text] [Related]
29. Can Risk Stratification Tools Be Utilized to Safely Discharge Low-Risk Febrile Neutropenic Patients from the Emergency Department?
Chen AY; Gottlieb M; Vilke GM; Coyne C
J Emerg Med; 2023 Jan; 64(1):111-118. PubMed ID: 36641256
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US.
Flanigan JA; Yasuda M; Chen CC; Li EC
Support Care Cancer; 2024 May; 32(6):373. PubMed ID: 38777864
[TBL] [Abstract][Full Text] [Related]
31. The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas.
Wang XJ; Goh DYT; Dorajoo SR; Chan A
Support Care Cancer; 2017 Sep; 25(9):2815-2822. PubMed ID: 28401314
[TBL] [Abstract][Full Text] [Related]
32. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
Chamilos G; Bamias A; Efstathiou E; Zorzou PM; Kastritis E; Kostis E; Papadimitriou C; Dimopoulos MA
Cancer; 2005 Jun; 103(12):2629-35. PubMed ID: 15856427
[TBL] [Abstract][Full Text] [Related]
33. Factors predicting outcome in high risk febrile neutropenia in patients receiving intensive chemotherapy for acute sleukemia: A prospective, observational study from South India.
Rajendranath R; Balasubramaniyum VK; Vijayakumar V; Ganesan P; Tenali GS
Indian J Cancer; 2014; 51(4):481-6. PubMed ID: 26842171
[TBL] [Abstract][Full Text] [Related]
34. Impact of time to antibiotics on outcomes of chemotherapy-induced febrile neutropenia.
Ko BS; Ahn S; Lee YS; Kim WY; Lim KS; Lee JL
Support Care Cancer; 2015 Sep; 23(9):2799-804. PubMed ID: 25663578
[TBL] [Abstract][Full Text] [Related]
35. Predictive Indicators to Identify High-Risk Paediatric Febrile Neutropenia in Paediatric Oncology Patients in a Middle-Income Country.
Green LL; Goussard P; van Zyl A; Kidd M; Kruger M
J Trop Pediatr; 2018 Oct; 64(5):395-402. PubMed ID: 29149345
[TBL] [Abstract][Full Text] [Related]
36. [Chemotherapy-induced febrile neutropenia: About 186 episodes. Clinical, microbiological and therapeutic characteristics].
Masmoudi S; Khanfir A; Maalej-Mezghan S; Hammami A; Frikha M
Tunis Med; 2015 Apr; 93(4):217-22. PubMed ID: 26375737
[TBL] [Abstract][Full Text] [Related]
37. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children.
Raisch DW; Holdsworth MT; Winter SS; Hutter JJ; Graham ML
Value Health; 2003; 6(2):158-66. PubMed ID: 12641866
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for refractory febrile neutropenia in urological chemotherapy.
Yasufuku T; Shigemura K; Tanaka K; Arakawa S; Miyake H; Fujisawa M
J Infect Chemother; 2013 Apr; 19(2):211-6. PubMed ID: 23011233
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department.
García de Guadiana-Romualdo L; Cerezuela-Fuentes P; Español-Morales I; Esteban-Torrella P; Jiménez-Santos E; Hernando-Holgado A; Albaladejo-Otón MD
Biochem Med (Zagreb); 2019 Feb; 29(1):010702. PubMed ID: 30591812
[TBL] [Abstract][Full Text] [Related]
40. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network.
Hui EP; Leung LK; Poon TC; Mo F; Chan VT; Ma AT; Poon A; Hui EK; Mak SS; Lai M; Lei KI; Ma BB; Mok TS; Yeo W; Zee BC; Chan AT
Support Care Cancer; 2011 Oct; 19(10):1625-35. PubMed ID: 20820815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
